FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's Humira (adalimumab) Prescribing Information

Article Link: FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie’s Humira (adalimumab) Prescribing Information



Source: FDA New Drug Approvals